Caristo Diagnostics Showcases Innovative AI Technology at ESC 2026: New Research on Stroke Prediction and Inflammation Detection
Caristo Diagnostics, a pioneer in artificial intelligence (AI) technologies tailored for cardiovascular health, is gearing up to present innovative research at the forthcoming European Society of Cardiology (ESC) Congress 2026. This significant event will take place from August 28 to 31 in Munich, Germany. Led by pioneering studies from the University of Oxford, these presentations will explore Caristo’s advanced AI platform, which includes emerging uses in non-contrast cardiac computed tomography (CT), stroke prediction, and virtual biopsies for artery inflammation.
The urgency of addressing cardiovascular diseases (CVDs) is underscored by alarming statistics, which show that CVDs remain the foremost cause of mortality worldwide. A staggering 85% of these fatalities arise from heart attacks and strokes, primarily driven by localized inflammation. This creates a crucial opportunity for earlier patient identification through routine imaging. At the ESC, late-breaking data will be unveiled by Professor Charalambos Antoniades, the British Heart Foundation Chair of Cardiovascular Medicine at the University of Oxford. His work will examine how Caristo's AI can predict stroke using standard cardiac CT scans, underlining the significance of their findings in clinical practice.
Additionally, the research to be showcased will feature the patented FAI-Score™, which assesses inflammatory signals that can be detected during non-contrast cardiac CT scans. Steve Deitsch, CEO of Caristo Diagnostics, stated, "Cardiovascular inflammation plays a pivotal role in the biology of cardiovascular disease. As our CaRi-Heart technology gains FDA authorization and is utilized clinically in the U.S., this research delves into the broader potential of our platform, highlighting our ongoing work to refine and expand FAI-Score's applications in non-contrast cardiac CT. We're excited to demonstrate our advancements in stroke prediction and the potential to combat cardiac illnesses beyond just coronary artery disease."
The details surrounding the ESC presentations featuring Caristo’s cutting-edge technologies are as follows:
1. Detecting Atrial Myopathy and Predicting Cardioembolic Stroke from Routine Cardiac CT
Session: Late-Breaking Clinical Science Advanced Cardiovascular Imaging
Presenter: Prof. Charalambos Antoniades
Date: Monday, August 31
Time: 2:15-3:15 p.m. CEST
Location: Prishtina (Hall A3)
2. Coronary Inflammation Quantified On Contrast and Non-Contrast Cardiac CT Identifies High-Risk Individuals Independently from Coronary Calcification Implications For Those With Zero Calcium Score
Session: From Pixels to Prognosis Imaging, Artificial Intelligence, and the Future of Coronary Artery Disease Diagnosis
Presenter: Prof. Kenneth Chan
Date: Monday, August 31
Time: 10:45-11:45 a.m. CEST
Location: Science Box 3 (Research Gateway-Hall A1)
3. Coronary Inflammation Predicts Cardiovascular Risk in the Absence of Standard Modifiable Risk Factors (SMuRFs)
Session: Predicting Cardio-Renal-Metabolic Disease
Presenter: Prof. Leanne Eveson
Date: Sunday, August 30
Time: 10:15-11:00 a.m. CEST
Location: Station 7 (Research Gateway-Hall A1)
4. ”Virtual Biopsy” of Arterial Cytokine Activation Predicts Long-Term Cardiac Mortality in Over 80,000 Patients from UK and USA
Session: Prevention Scores Risk Prediction and Polygenic Risk
Presenter: Prof. Christos Kotanidis
Date: Saturday, August 29
Time: 3:45-4:45 p.m. CEST
Location: Science Box 2 (Research Gateway-Hall A1)
The University of Oxford will also conduct specialized sessions underscoring the increasing role of AI in managing cardiovascular diseases and refining risk stratification:
Date: Friday, August 28
Time: 8:15-9:45 a.m. CEST
Location: Beirut (Hall A3)
Date: Sunday, August 30
Time: 1:45-3:00 p.m. CEST
Location: Digital Health Stage (Hall B3)
The forthcoming research presentations at ESC are poised to illuminate future applications of Caristo's technologies, which differ significantly from their current clinical offerings. Caristo's CaRi-Heart® technology has earned FDA De Novo marketing authorization, making it the first system in the U.S. that quantifies coronary inflammation derived from standard coronary CT angiography (CCTA). Having become commercially available in the U.S., UK, Switzerland, and Australia, Caristo's innovations in AI are setting a precedent in the cardiovascular field. The CaRi-Plaque® technology complements CaRi-Heart by providing analysis of coronary plaque and stenosis through FDA clearance for AI-assisted diagnostics.
Caristo Diagnostics was founded as a spin-off from the University of Oxford and has rapidly established itself as a leader in cardiovascular health AI solutions. Its award-winning CaRi-Heart® technology is designed to detect latent heart conditions and identify individuals at risk for heart attacks even before symptoms emerge. Through partnerships with esteemed hospitals, research institutions, and pharmaceutical firms, Caristo Diagnostics is committed to saving lives through early interventions and tailored preventive measures. The company has also been recognized as a Technology Pioneer by the World Economic Forum in June 2026. For further information, visit www.caristo.com or follow Caristo on social media platforms such as LinkedIn, YouTube, and X.
The urgency of addressing cardiovascular diseases (CVDs) is underscored by alarming statistics, which show that CVDs remain the foremost cause of mortality worldwide. A staggering 85% of these fatalities arise from heart attacks and strokes, primarily driven by localized inflammation. This creates a crucial opportunity for earlier patient identification through routine imaging. At the ESC, late-breaking data will be unveiled by Professor Charalambos Antoniades, the British Heart Foundation Chair of Cardiovascular Medicine at the University of Oxford. His work will examine how Caristo's AI can predict stroke using standard cardiac CT scans, underlining the significance of their findings in clinical practice.
Additionally, the research to be showcased will feature the patented FAI-Score™, which assesses inflammatory signals that can be detected during non-contrast cardiac CT scans. Steve Deitsch, CEO of Caristo Diagnostics, stated, "Cardiovascular inflammation plays a pivotal role in the biology of cardiovascular disease. As our CaRi-Heart technology gains FDA authorization and is utilized clinically in the U.S., this research delves into the broader potential of our platform, highlighting our ongoing work to refine and expand FAI-Score's applications in non-contrast cardiac CT. We're excited to demonstrate our advancements in stroke prediction and the potential to combat cardiac illnesses beyond just coronary artery disease."
The details surrounding the ESC presentations featuring Caristo’s cutting-edge technologies are as follows:
1. Detecting Atrial Myopathy and Predicting Cardioembolic Stroke from Routine Cardiac CT
Session: Late-Breaking Clinical Science Advanced Cardiovascular Imaging
Presenter: Prof. Charalambos Antoniades
Date: Monday, August 31
Time: 2:15-3:15 p.m. CEST
Location: Prishtina (Hall A3)
2. Coronary Inflammation Quantified On Contrast and Non-Contrast Cardiac CT Identifies High-Risk Individuals Independently from Coronary Calcification Implications For Those With Zero Calcium Score
Session: From Pixels to Prognosis Imaging, Artificial Intelligence, and the Future of Coronary Artery Disease Diagnosis
Presenter: Prof. Kenneth Chan
Date: Monday, August 31
Time: 10:45-11:45 a.m. CEST
Location: Science Box 3 (Research Gateway-Hall A1)
3. Coronary Inflammation Predicts Cardiovascular Risk in the Absence of Standard Modifiable Risk Factors (SMuRFs)
Session: Predicting Cardio-Renal-Metabolic Disease
Presenter: Prof. Leanne Eveson
Date: Sunday, August 30
Time: 10:15-11:00 a.m. CEST
Location: Station 7 (Research Gateway-Hall A1)
4. ”Virtual Biopsy” of Arterial Cytokine Activation Predicts Long-Term Cardiac Mortality in Over 80,000 Patients from UK and USA
Session: Prevention Scores Risk Prediction and Polygenic Risk
Presenter: Prof. Christos Kotanidis
Date: Saturday, August 29
Time: 3:45-4:45 p.m. CEST
Location: Science Box 2 (Research Gateway-Hall A1)
The University of Oxford will also conduct specialized sessions underscoring the increasing role of AI in managing cardiovascular diseases and refining risk stratification:
- - Great Debates: Coronary Computed Tomography for Cardiovascular Disease Prevention in the Era Of Artificial Intelligence
Date: Friday, August 28
Time: 8:15-9:45 a.m. CEST
Location: Beirut (Hall A3)
- - Clinical Case Management Using Artificial Intelligence to Guide Treatments in Practice - Co-Pilot for Risk Stratification
Date: Sunday, August 30
Time: 1:45-3:00 p.m. CEST
Location: Digital Health Stage (Hall B3)
The forthcoming research presentations at ESC are poised to illuminate future applications of Caristo's technologies, which differ significantly from their current clinical offerings. Caristo's CaRi-Heart® technology has earned FDA De Novo marketing authorization, making it the first system in the U.S. that quantifies coronary inflammation derived from standard coronary CT angiography (CCTA). Having become commercially available in the U.S., UK, Switzerland, and Australia, Caristo's innovations in AI are setting a precedent in the cardiovascular field. The CaRi-Plaque® technology complements CaRi-Heart by providing analysis of coronary plaque and stenosis through FDA clearance for AI-assisted diagnostics.
Caristo Diagnostics was founded as a spin-off from the University of Oxford and has rapidly established itself as a leader in cardiovascular health AI solutions. Its award-winning CaRi-Heart® technology is designed to detect latent heart conditions and identify individuals at risk for heart attacks even before symptoms emerge. Through partnerships with esteemed hospitals, research institutions, and pharmaceutical firms, Caristo Diagnostics is committed to saving lives through early interventions and tailored preventive measures. The company has also been recognized as a Technology Pioneer by the World Economic Forum in June 2026. For further information, visit www.caristo.com or follow Caristo on social media platforms such as LinkedIn, YouTube, and X.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.